Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
883.2 USD | -0.84% | -1.52% | +0.56% |
Apr. 26 | Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says | MT |
Apr. 26 | Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125 | MT |
Official Publications
SEC Filing 10K | CO | |
SEC Filing 8K | CO | |
Slide show results | CO | |
Annual results | CO | |
SEC Filing 8K | CO | |
SEC Filing 8K | CO | |
3rd quarter results | CO | |
SEC Filing 10Q-3 | CO | |
Slide show Q3 | CO | |
Slide show half-year results | CO | |
1st-half-year results | CO | |
SEC Filing 10Q-2 | CO | |
SEC Filing 8K | CO | |
Slide show Q1 | CO | |
SEC Filing 10Q-1 | CO | |
1st quarter results | CO | |
Proxy Statments | CO | |
Annual ESG Report | CO | |
SEC Filing 10K | CO | |
SEC Filing 8K | CO | |
Slide show results | CO | |
Annual results | CO | |
SEC Filing 13G | CO | |
3rd quarter results | CO | |
Slide show Q3 | CO |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Official Publications